Table 2.
Baseline characteristics in the derivation and validation cohorts.
| Derivation cohort | Validation cohort | P-value | |
|---|---|---|---|
| (n = 353) | (n = 113) | ||
| Age, years | 66.1 ± 12.1 | 65.4 ± 11.8 | 0.617 |
| Male, n (%) | 280 (79.3) | 93 (82.3) | 0.490 |
| Hypertension, n (%) | 227 (64.3) | 76 (67.2) | 0.567 |
| Dyslipidemia, n (%) | 198 (56.1) | 66 (58.4) | 0.665 |
| Diabetes, n (%) | 144 (40.8) | 55 (48.7) | 0.141 |
| Old CVA, n (%) | 19 (5.4) | 8 (7) | 0.502 |
| CKD, n (%) | 95 (26.9) | 37 (32.7) | 0.231 |
| Prior PCI, n (%) | 74 (21) | 16 (14.2) | 0.111 |
| Prior CABG, n (%) | 34 (6.6) | 11 (9.7) | 0.974 |
| CAG, n (%) | 334 (94.6) | 103 (91.2) | 0.184 |
| PCI, n (%) | 238 (67.4) | 77 (68.l) | 0.887 |
| CABG, n (%) | 63 (17.8) | 17 (15) | 0.492 |
| Triple vessel disease at index CAG, n (%)* | 224 (67.1) | 73 (70.9) | 0.469 |
| LVEF, % | 51.0 ± 12.4 | 51.9 ± 13.7 | 0.538 |
| LVEF <40%, n (%) | 67 (19) | 28 (24.8) | 0.183 |
| RWMA, n (%) | 189 (53.5) | 53 (46.9) | 0.219 |
| Total cholesterol, mg/dL | 178.1 ± 73.1 | 176 ± 45.2 | 0.769 |
| Triglyceride, mg/dL | 160.4 ± 143.2 | 159.1 ± 117.6 | 0.930 |
| HDL-C, mg/dL | 39.6 ± 14.3 | 39 ± 11.4 | 0.720 |
| LDL-C, mg/dL | 109.4 ± 43 | 109.6 ± 38.4 | 0.960 |
| TIMI score | 3.8 ± 1.4 | 4.0 ± 1.6 | 0.189 |
| GRACE score | 136 ± 38.4 | 134.4 ± 41.0 | 0.708 |
| Hospital stays, days | 8.5 ± 10.1 | 8.7 ± 12.7 | 0.833 |
| Peak troponin I, ng/mL | 21.8 ± 100.7 | 21.4 ± 36.2 | 0.971 |
RWMA, regional wall motion abnormalities. Other abbreviations as in Table 1.
*
n (denominator) = 334 in the derivation cohort and n = 103 in the validation cohort.